Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) Equity Average (2021 - 2025)

Aligos Therapeutics' Equity Average history spans 5 years, with the latest figure at $62.7 million for Q4 2025.

  • For Q4 2025, Equity Average rose 493.56% year-over-year to $62.7 million; the TTM value through Dec 2025 reached $62.7 million, up 493.56%, while the annual FY2025 figure was $12.3 million, 61.06% down from the prior year.
  • Equity Average reached $62.7 million in Q4 2025 per ALGS's latest filing, down from $86.8 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $200.9 million in Q4 2021 to a low of $10.6 million in Q4 2024.
  • Average Equity Average over 5 years is $102.7 million, with a median of $86.8 million recorded in 2025.
  • Peak YoY movement for Equity Average: crashed 85.62% in 2024, then surged 493.56% in 2025.
  • A 5-year view of Equity Average shows it stood at $200.9 million in 2021, then tumbled by 43.77% to $113.0 million in 2022, then crashed by 34.97% to $73.5 million in 2023, then plummeted by 85.62% to $10.6 million in 2024, then soared by 493.56% to $62.7 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Equity Average are $62.7 million (Q4 2025), $86.8 million (Q3 2025), and $109.2 million (Q2 2025).